Boston Scientific Shares (Diluted) decreased by 0.0% to 1.5B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from 1.5B to 1.5B. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to basic shares indicates a higher reliance on equity-based compensation or convertible debt financing.
Weighted-average shares outstanding (diluted) includes the total number of basic common shares plus all additional share...
Commonly compared against basic shares to determine the 'dilution overhang' present in a company's capital structure.
weighted_shares_diluted| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| QoQ Change | — | +0.2% | +0.2% | -0.0% | +0.2% | +0.4% | +0.7% | +1.3% | +0.5% | +0.2% | +0.2% | +0.4% | +0.0% | +0.1% | -0.0% |
| YoY Change | — | — | — | +0.4% | +0.3% | +0.5% | +1.3% | +2.4% | +2.5% | +1.9% | +0.8% | +0.8% | +0.6% | +0.5% | +0.1% |